King Luther Capital Management Corp Acquires 17,343 Shares of DexCom, Inc. $DXCM

King Luther Capital Management Corp increased its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 7.1% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 259,993 shares of the medical device company’s stock after acquiring an additional 17,343 shares during the quarter. King Luther Capital Management Corp owned approximately 0.07% of DexCom worth $22,695,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the business. Brighton Jones LLC boosted its holdings in shares of DexCom by 257.7% in the 4th quarter. Brighton Jones LLC now owns 16,582 shares of the medical device company’s stock worth $1,290,000 after buying an additional 11,946 shares during the last quarter. Envestnet Asset Management Inc. grew its position in shares of DexCom by 9.3% during the 1st quarter. Envestnet Asset Management Inc. now owns 638,170 shares of the medical device company’s stock valued at $43,581,000 after acquiring an additional 54,105 shares during the period. Stratos Wealth Partners LTD. grew its position in shares of DexCom by 32.7% during the 1st quarter. Stratos Wealth Partners LTD. now owns 3,428 shares of the medical device company’s stock valued at $234,000 after acquiring an additional 845 shares during the period. Allworth Financial LP increased its stake in shares of DexCom by 163.3% during the 1st quarter. Allworth Financial LP now owns 2,846 shares of the medical device company’s stock worth $201,000 after purchasing an additional 1,765 shares during the last quarter. Finally, Alps Advisors Inc. raised its holdings in shares of DexCom by 43.8% in the 1st quarter. Alps Advisors Inc. now owns 17,137 shares of the medical device company’s stock worth $1,170,000 after purchasing an additional 5,219 shares during the period. Institutional investors own 97.75% of the company’s stock.

DexCom Stock Performance

DexCom stock opened at $55.00 on Monday. DexCom, Inc. has a 1-year low of $54.11 and a 1-year high of $93.25. The company has a current ratio of 1.52, a quick ratio of 1.35 and a debt-to-equity ratio of 0.48. The firm has a market capitalization of $21.45 billion, a PE ratio of 38.19, a price-to-earnings-growth ratio of 1.43 and a beta of 1.40. The firm’s 50 day simple moving average is $69.24 and its 200 day simple moving average is $77.72.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, October 30th. The medical device company reported $0.61 EPS for the quarter, topping the consensus estimate of $0.57 by $0.04. DexCom had a return on equity of 30.41% and a net margin of 13.29%.The business had revenue of $1.21 billion during the quarter, compared to analysts’ expectations of $1.18 billion. During the same period in the previous year, the business earned $0.45 earnings per share. The firm’s revenue was up 21.6% on a year-over-year basis. DexCom has set its FY 2025 guidance at EPS. As a group, analysts expect that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Insider Activity at DexCom

In other news, Director Kyle Malady sold 667 shares of the firm’s stock in a transaction on Friday, September 5th. The shares were sold at an average price of $80.86, for a total transaction of $53,933.62. Following the sale, the director owned 22,667 shares in the company, valued at approximately $1,832,853.62. This trade represents a 2.86% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Michael Jon Brown sold 500 shares of the company’s stock in a transaction on Friday, August 15th. The stock was sold at an average price of $80.29, for a total transaction of $40,145.00. Following the completion of the transaction, the executive vice president owned 94,102 shares of the company’s stock, valued at $7,555,449.58. This trade represents a 0.53% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 5,383 shares of company stock worth $434,274 over the last quarter. 0.32% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

DXCM has been the subject of a number of recent research reports. Stifel Nicolaus started coverage on DexCom in a research note on Tuesday, October 21st. They issued a “buy” rating and a $85.00 target price on the stock. Morgan Stanley boosted their price objective on DexCom from $82.00 to $89.00 and gave the company an “equal weight” rating in a research note on Tuesday, July 15th. Barclays set a $80.00 target price on shares of DexCom and gave the stock an “equal weight” rating in a research note on Monday, November 3rd. Citigroup dropped their price target on shares of DexCom from $85.00 to $75.00 and set a “buy” rating on the stock in a research note on Friday, October 31st. Finally, Canaccord Genuity Group set a $99.00 price objective on shares of DexCom and gave the company a “buy” rating in a research note on Friday, October 31st. Three investment analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $88.86.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.